-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
The esophagus was once viewed mainly as a passageway between the mouth and stomach, with little microbial activity of its own. Advances in sequencing have changed that perspective. Researchers now recognize a dynamic microbial community in the esophageal lumen and mucosal surface, shaped by saliva, swallowed food, refluxed gastric contents, immune defenses, and local tissue conditions.
The phrase “The Microbiome of the Esophagus in Health and Disease” captures an expanding area of gastroenterology and esophageal research. It also reflects the kind of interdisciplinary subject discussed through the International Society for Diseases of the Esophagus and its 2021 World Congress, where scientific sessions and research abstracts addressed the biological mechanisms behind esophageal disorders.
Studying this ecosystem may improve understanding of reflux disease, Barrett’s esophagus, esophageal adenocarcinoma, squamous cell carcinoma, and motility disorders. However, the field remains young, and findings must be interpreted carefully because sampling methods, medications, diet, and oral bacteria can strongly influence results.
The esophagus does not contain a stable microbial community in the same way that the colon does. Microorganisms enter continuously from the mouth with saliva and food, while swallowing and peristalsis regularly clear material toward the stomach. This creates a changing environment rather than a densely populated, long-residence habitat.
Local conditions still matter. Mucus, epithelial cells, oxygen exposure, immune signaling, and brief contact with acid or bile can favor particular organisms. The esophageal microbiota may therefore differ from oral and gastric communities, although overlap is expected and remains a major issue in study design.
Healthy esophageal samples commonly contain organisms associated with the oral cavity, including members of the Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria groups. The exact composition varies between individuals and between studies. Bacterial DNA is easier to detect than living organisms, so sequencing results do not always show which microbes are active.
The healthy mucosa likely exists in a balanced relationship with its microbial surroundings. Epithelial barriers and innate immune responses help prevent excessive inflammation, while microbial metabolites and surface interactions may influence tissue behavior. Fungi and viruses may also contribute, but they have received less attention than bacteria.
Gastroesophageal reflux disease can alter the environment experienced by esophageal microbes. Repeated exposure to acid and bile may damage the epithelial barrier, change mucus properties, and select for organisms that tolerate stressful conditions. Inflammation may then affect the microbial community, creating a feedback loop between tissue injury and dysbiosis.
Research has reported differences in microbial profiles between healthy individuals and people with reflux esophagitis or Barrett’s esophagus. Some studies have identified increased representation of Gram-negative organisms in diseased tissue, potentially relevant because bacterial components can stimulate inflammatory pathways. These associations do not prove that microbiota changes cause reflux or precancerous transformation.
| Research setting | What it can reveal | Main limitation |
|---|---|---|
| Saliva or swallowed contents | Microbes entering the esophagus | May reflect the oral microbiome more than esophageal tissue |
| Mucosal biopsy | Organisms associated with the epithelial surface | Invasive sampling and possible contamination |
| Reflux or gastric samples | Microbial exposure from below | Does not represent the entire esophageal environment |
| 16S rRNA sequencing | Broad bacterial community composition | Limited species-level and functional information |
| Metagenomic sequencing | Genes, species, and potential pathways | Higher cost and complex data interpretation |
| Culture-based testing | Living organisms and antimicrobial sensitivity | Many organisms are difficult to grow |
Barrett’s esophagus develops when chronic injury and repair lead to a change in the lining of the lower esophagus. Its connection with the microbiome is under active investigation. Altered bacteria may influence inflammation, epithelial differentiation, oxidative stress, and the production of metabolites that affect cellular signaling.
Cancer research is examining whether microbial signatures can distinguish malignant, precancerous, and non-malignant tissue. Esophageal adenocarcinoma and squamous cell carcinoma have different risk factors and biological pathways, so their microbial associations may not be identical. At present, microbial profiles are research tools rather than validated replacements for endoscopy, biopsy, or histopathology.
Reliable sampling is central to esophageal microbiome research. A specimen can be affected by recent meals, oral hygiene, proton pump inhibitors, antibiotics, smoking, alcohol use, and the method used to collect it. Researchers must also control for contamination because low-biomass samples can be influenced by DNA from instruments, reagents, or the mouth.
Sequencing can describe which organisms are present, while transcriptomic, proteomic, and metabolomic approaches may show what those organisms are doing. Combining these methods with endoscopic appearance, pathology, symptoms, and treatment history may produce a more clinically meaningful picture than relying on bacterial abundance alone.
Microbiome research could eventually support risk assessment for Barrett’s progression, identify patients likely to respond to particular therapies, or reveal new targets for prevention. It may also clarify why some people develop persistent inflammation while others with similar reflux exposure do not.
Probiotics, dietary modification, microbial metabolites, and targeted antimicrobial strategies are possible areas of study. Yet broad antibiotic treatment could cause harm by disrupting protective organisms and promoting resistance. Any microbiome-directed therapy would require controlled trials, clear biological targets, and evidence that changing the community improves patient outcomes.
Future studies will benefit from standardized collection protocols, larger and more diverse patient groups, and repeated sampling over time. Researchers should distinguish between microbial DNA, viable organisms, and functional activity rather than treating all sequencing signals as equivalent.
Useful priorities include:
The esophageal microbiome offers a promising lens for understanding health, inflammation, metaplasia, and cancer biology. Continued collaboration among gastroenterologists, surgeons, pathologists, microbiologists, and computational scientists will be essential. Educational resources and research discussions connected with ISDE can help clinicians follow this rapidly developing field and translate credible findings into better esophageal care.